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ABSTRACT 
The platinum-containing drug cisplatin plays a key role in the curative and 
palliative treatment of many solid malignancies. Unfortunately, the 
treatment can lead to sensorineural hearing loss, which limits the use of the 
drug. High single and cumulative dose levels are risk factors, but there is a 
large interindividual variability in the susceptibility to the ototoxic effects. 
The mechanisms behind the ototoxicity have not been fully elucidated, but 
one hallmark is oxidative stress. Moreover, the ototoxicity is dependent on 
the exposure of cisplatin and/or its biotransformation product MHC in the 
perilymphatic compartment of the cochlea. The aim of the research 
presented in this thesis was to contribute to the development of treatment 
strategies against cisplatin-induced ototoxicity. 
Sulfur-containing nucleophiles are attractive candidate compounds against 
cisplatin-induced hearing loss since they are prone to chemically interact with 
cisplatin and MHC and could potentially reduce the exposure of these platinum 
species in the cochlea. A second possible mechanism may be relief of oxidative 
stress. The aim of the in vitro study described in Paper I was to investigate how 
quickly the concentrations of cisplatin and MHC can be reduced in the presence 
of five sulfur-containing nucleophiles. The results showed that thiosulfate was a 
promising candidate for future studies in vivo, since it reacted fast with cisplatin 
and, in particular, with MHC. This conclusion was further supported by the fact 
that thiosulfate is an endogenous ion, is well tolerated, and has been used 
clinically for decades against e.g. cyanide poisoning. 
Systemic administration of thiosulfate has earlier been investigated in several in 
vitro and in vivo studies against cisplatin-induced ototoxicity. However, it has 
been unknown whether thiosulfate at all reaches the cochlea. In the study 
described in Paper II, it was demonstrated that the distribution of thiosulfate to 
the perilymphatic compartment was quick and extensive after an i.v. bolus 
injection in guinea pigs. Unfortunately, this way of administration of thiosulfate 
in connection with systemic cisplatin delivery is risky, since it may lead to 
decreased antitumoral effects due to inactivation of cisplatin and MHC not only 
in the cochlea but also in tumor tissues. In the studies on which Paper III is 
based, it was found that the ototoxicity in cisplatin-treated guinea pigs was 
reduced by a local administration strategy employing a thiosulfate-containing 
hyaluronan gel administered into the middle ear cavity three hours prior to the 
systemic cisplatin injection. 
When quantifying cisplatin, unselective methods are almost always used, which 
may confound the results. In the final study, on which Paper IV is based, a 
sensitive, robust, and fast method using liquid chromatography and UV 
detection for the selective analysis of cisplatin in blood was developed. This 
method will be a valuable instrument in future studies exploring the role of 
pharmacokinetic parameters of cisplatin for the ototoxic effects. 
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